Axsome Therapeutics, Inc.
AXSM
$158.88
$1.010.64%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -183.17M | -229.53M | -246.90M | -278.27M | -287.22M |
| Total Depreciation and Amortization | 9.06M | 8.86M | 8.51M | 8.26M | 7.96M |
| Total Amortization of Deferred Charges | 1.30M | 1.85M | 2.36M | 2.69M | 2.64M |
| Total Other Non-Cash Items | 102.46M | 121.18M | 122.47M | 118.87M | 114.73M |
| Change in Net Operating Assets | -23.06M | -3.32M | -7.08M | 30.14M | 33.48M |
| Cash from Operations | -93.41M | -100.95M | -120.63M | -118.32M | -128.41M |
| Capital Expenditure | -480.00K | -439.00K | -471.00K | -510.00K | -270.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -480.00K | -439.00K | -471.00K | -510.00K | -270.00K |
| Total Debt Issued | 330.00M | 260.00M | 190.00M | -- | -- |
| Total Debt Repaid | -334.11M | -263.90M | -193.55M | -1.23M | -990.00K |
| Issuance of Common Stock | 127.46M | 124.02M | 131.94M | 105.65M | 71.46M |
| Repurchase of Common Stock | -7.11M | -6.60M | -6.23M | -6.67M | -3.95M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -14.78M | -14.19M | -13.70M | -9.45M | -8.68M |
| Cash from Financing | 101.47M | 99.32M | 108.46M | 88.30M | 57.84M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 7.58M | -2.07M | -12.64M | -30.53M | -70.84M |